Biodesix expands Series E funding stash for personalized lung cancer treatment Dx

Colorado molecular diagnostics outfit Biodesix has come close to doubling a Series E financing that it first announced in December. The company, which is developing a personalized medicine-focused lung cancer test, initially raised $8.3 million for the round in a mix of both new funding and the conversion of a convertible note. But Biodesix has now pulled in another $6.1 million from a follow-on sale of preferred shares. Execs plan on using the now-$14.4 million cash infusion to help advance its VeriStrat serum protein test that helps physicians figure out the best treatment for patients with advanced non-small cell lung cancer. Item

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.